| Index | — | P/E | — | EPS (ttm) | -1.00 | Insider Own | 0.16% | Shs Outstand | 68.64M | Perf Week | 6.88% |
| Market Cap | 1.41B | Forward P/E | — | EPS next Y | -1.83 | Insider Trans | 0.00% | Shs Float | 50.91M | Perf Month | -10.64% |
| Enterprise Value | 1.04B | PEG | — | EPS next Q | -0.31 | Short Float | 3.95% | Perf Quarter | -29.60% | ||
| Income | -62.00M | P/S | — | EPS this Y | — | Short Ratio | 7.22 | Perf Half Y | -5.49% | ||
| Sales | 0.00 | P/B | 3.92 | EPS next Y | — | ROA | -16.72% | Short Interest | 2.01M | Perf YTD | 61.42% |
| Book/sh | 5.23 | P/C | 3.88 | EPS next 5Y | — | ROE | -20.86% | 52W High | 31.44 -34.80% | Perf Year | 63.48% |
| Cash/sh | 5.29 | P/FCF | — | EPS past 3/5Y | — | ROIC | -19.85% | 52W Low | 12.04 70.27% | Perf 3Y | 173.70% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 6.36% 5.65% | Perf 5Y | 36.67% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.20 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 28.70 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 46.00 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 28.70 | EPS Q/Q | -53.33% | SMA20 | 4.00% | Beta | 1.35 | Target Price | 48.83 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | — | SMA50 | -14.23% | Rel Volume | 1.82 | Prev Close | 20.86 |
| Employees | 73 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | -4.94% | Avg Volume | 297.61K | Price | 20.50 |
| IPO Date | Jun 25, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 24.34% — | Net Debt/EBITDA | — | Volume | 542,837 | Change | -1.73% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-10-26 | Reiterated | New Street | $65 | |
| Aug-07-26 | Reiterated | Guggenheim | Buy | $34 → $40 |
| Aug-07-26 | Reiterated | Cantor Fitzgerald | Overweight | $35 → $40 |
| Aug-06-26 | Reiterated | Needham | Buy | $32 → $39 |
| Jul-27-26 | Initiated | Wells Fargo | Overweight | $44 |
| May-19-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $65 |
| May-15-26 | Reiterated | Cantor Fitzgerald | Overweight | $35 |
| Mar-10-26 | Reiterated | Guggenheim | Buy | $29 → $34 |
| Mar-06-26 | Reiterated | Needham | Buy | $29 → $32 |
| Jan-23-26 | Reiterated | RBC Capital | Outperform | $40 |
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 24 | 22 | 15 | 11 | — | — | — | — | |
| Research and Development | 46 | 39 | 35 | 30 | — | — | — | — | |
| Other Operating Expense | 1 | -1 | 0 | 0 | — | — | — | — | |
| Operating Income | -72 | -61 | -50 | -41 | — | — | — | — | |
| Interest Expense | 0 | 0 | 1 | 1 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | 13 | 12 | 6 | — | — | — | — | |
| Net Income Before Taxes | -62 | -48 | -39 | -36 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -62 | -48 | -39 | -36 | — | — | — | — | |
| Net Income From Continuing Operations | -62 | -48 | -39 | -36 | — | — | — | — | |
| Net Income | -62 | -48 | -39 | -36 | — | — | — | — | |
| EPS (Recurring) | -1.00 | -0.79 | -0.75 | -0.68 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.00 | -0.79 | -0.75 | -0.68 | — | — | — | — | |
| EPS (Diluted) | -1.00 | -0.79 | -0.75 | -0.68 | — | — | — | — | |
| EBITDA | -62 | -47 | -39 | -35 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 67 | 61 | 52 | 52 | — | — | — | — | |
| Market Capitalization | 1,374 | 775 | 364 | 302 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |